Edgewise Therapeutics Inc.
- Address
- 1715 38th Street
Sponsor Overview
Specializations
Muscular Dystrophy Research
Edgewise Therapeutics Inc. focuses on Becker muscular dystrophy, including BMD in both adult and adolescent populations, with additional interest in related limb-girdle muscular dystrophy subtypes.
- Becker muscular dystrophy
- Adolescent neuromuscular disease
- Limb-girdle muscular dystrophy
The sponsored studies examine muscle integrity, skeletal muscle function, and markers linked to muscle damage in these inherited disorders.
Neuromuscular Disease Biomarker Studies
The sponsor supports research in broader neuromuscular disease settings, with attention to circulating indicators of disease activity and tissue injury.
- Serum creatine kinase
- Biomarkers of muscle damage
- Clinical response assessment
These trials include measurement of CK and other biomarker changes in adults with muscular dystrophy and related muscle disorders.
Metabolic Myopathy and Muscle Energy Disorders
Edgewise Therapeutics also funds studies in McArdle disease, reflecting interest in inherited disorders that affect muscle metabolism and exercise tolerance.
- McArdle disease
- Muscle metabolism
- Exercise-related muscle symptoms
Research in this area addresses the safety profile of treatment in adults with metabolic muscle disease and associated biomarker changes.
Long-term Treatment in Chronic Muscle Disease
The clinical portfolio includes extended follow-up in people living with chronic muscle disease, with emphasis on ongoing tolerability and sustained disease monitoring.
- Long-term safety
- Chronic neuromuscular disorders
- Extended treatment exposure
This area covers adult and adolescent participants across inherited muscle conditions managed in multi-site, international clinical research.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarker Response to Exercise in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy |  Denmark | Not Recruiting |
| A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy |  Belgium Denmark France Germany Italy Spain The Netherlands | Not Recruiting |
| Long-term Safety and Biomarker Assessment of EDG-5506 in Adults and Adolescents with Becker Muscular Dystrophy: An Open-Label Extension Study | Belgium Denmark France Germany Italy Spain The Netherlands | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 17 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases3 trials238 other sponsors
- 2.Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials165 other sponsors
Partnered Research Centres
17 centres- Address
- Albinusdreef 2, 2333 ZA Leiden
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- Boulevard Du Douzieme De Ligne 1, 4000 Liège
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Edgewise Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.